Sit Investment Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Sit Investment Associates’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-9,900	Closed	-$863K	–	518
2016 Q3	$863K	Hold	9,900	–	–	0.02%	320
2016 Q2	$852K	Sell	9,900 -3,400	-26%	-$294K	0.02%	323
2016 Q1	$1.06M	Hold	13,300	–	–	0.02%	313
2015 Q4	$1.67M	Hold	13,300	–	–	0.03%	261
2015 Q3	$1.39M	Hold	13,300	–	–	0.03%	288
2015 Q2	$1.64M	Hold	13,300	–	–	0.03%	264
2015 Q1	$1.57M	Sell	13,300 -900	-6%	-$108K	0.03%	266
2014 Q4	$1.69M	Hold	14,200	–	–	0.03%	280
2014 Q3	$1.59M	Hold	14,200	–	–	0.03%	293
2014 Q2	$1.34M	Hold	14,200	–	–	0.02%	318
2014 Q1	$1M	Hold	14,200	–	–	0.02%	348
2013 Q4	$1.05M	Hold	14,200	–	–	0.02%	349
2013 Q3	$1.08M	Hold	14,200	–	–	0.02%	330
2013 Q2	$1.14M	Buy	+14,200	New	+$1.05M	0.02%	318

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Sit Investment Associates's VRTX Position: Q4 2016 in Review

Sit Investment Associates sold out of Vertex Pharmaceuticals (VRTX) in Q4 2016, closing a stake of 9,900 shares — an estimated $863K sold.

Sit Investment Associates first reported a position in VRTX in Q2 2013 and held it in 14 quarters. The position peaked at $1.69M in Q4 2014. 483 funds tracked by Wall St. Rank hold VRTX as of Q4 2016.

Sit Investment Associates reported no remaining Vertex Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Sit Investment Associates sold 9,900 Vertex Pharmaceuticals shares in Q4 2016, an estimated $863K.
Sit Investment Associates first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 14 quarters.
Sit Investment Associates's Vertex Pharmaceuticals position peaked at $1.69M in Q4 2014.
483 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2016.

Based on Sit Investment Associates's 13F filing for Q4 2016, filed 19 Jan 2017.